Dogwood Therapeutics Reaches Milestone in Halneuron Phase 2b Trial

Dogwood Therapeutics, Inc. has announced significant progress in its ongoing HALT-CINP Phase 2b trial. This pivotal study, targeting chemotherapy-induced neuropathic pain, has now enrolled its first 100 patients. Conducted at approximately 25 sites across the US, the trial focuses on the safety and efficacy of Halneuron® compared to a placebo.

The low early termination rate among the 80 initial completers suggests good tolerance. The interim analysis is set for late 2025. A key objective is adjusting the sample size to ensure statistical significance. The target remains 200 patients, with final results expected by mid-2026.

This study addresses a critical unmet need, as highlighted by Dogwood's Chief Medical Officer, Dr. R. Michael Gendreau. Halneuron® is a promising non-opioid analgesic, granted fast track designation by the FDA for its potential to alleviate cancer and chemotherapy-related pain.